Sigma-Tau Pharmaceuticals Inc., a research-based pharmaceutical company, has changed its name to Leadiant Biosciences Inc.
The company's Feb. 28 announcement coincided with Rare Disease Day 2017, which is a worldwide campaign to raise awareness of rare diseases and improve people's access to treatments and medical representation, as well as help others whose lives are affected by a rare condition.
“Rare Disease Day (was) the perfect time to unveil our new name and reaffirm our commitment to the study of rare diseases, which has been an integral part of our heritage dating back to 1984 when we became only the fourth company in the world to receive an Orphan Drug Designation in the U.S.,” Michael Minarich, CEO of Leadiant Biosciences, said in the announcement.
“In 2017, Leadiant Biosciences will realize several important and exciting milestones in our product pipeline, as well as continuing multiple ongoing clinical trials,” Minarich said.
Sigma-Tau Pharmaceuticals changes name to Leadiant Biosciences
Organizations in this Story
Want to get notified whenever we write about Sigma-Tau Pharmaceuticals ?
Next time we write about Sigma-Tau Pharmaceuticals, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts